
Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

French Ipsen falls after Epizyme take-over announcement
Even if Ipsen succeeds in halving the losses at Epizyme Inc, this would reduce the group's profit by nine percent by 2024, Credit Suisse analysts...
Commission to establish EU health data space
The EU Commission is set to present a draft law on a "European health data area" this Tuesday, which could be a big thing for digital...

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...